X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3659) 3659
Publication (602) 602
Newsletter (146) 146
Newspaper Article (27) 27
Book Chapter (25) 25
Book Review (25) 25
Conference Proceeding (11) 11
Magazine Article (9) 9
Dissertation (4) 4
Trade Publication Article (3) 3
Paper (2) 2
Transcript (2) 2
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dasatinib (3371) 3371
humans (2439) 2439
index medicus (2163) 2163
oncology (1395) 1395
imatinib (1092) 1092
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (993) 993
hematology (978) 978
chronic myeloid leukemia (885) 885
female (881) 881
male (852) 852
imatinib mesylate (851) 851
pyrimidines - therapeutic use (823) 823
nilotinib (817) 817
protein kinase inhibitors - therapeutic use (804) 804
chronic myelogenous leukemia (789) 789
chronic myeloid-leukemia (714) 714
middle aged (676) 676
antineoplastic agents - therapeutic use (665) 665
cancer (653) 653
thiazoles - therapeutic use (629) 629
protein kinase inhibitors - pharmacology (606) 606
pyrimidines - pharmacology (593) 593
adult (587) 587
animals (579) 579
aged (544) 544
benzamides (535) 535
leukemia (534) 534
research (508) 508
hemic and lymphatic diseases (465) 465
thiazoles - pharmacology (465) 465
cell line, tumor (461) 461
tyrosine (442) 442
bcr-abl (433) 433
treatment outcome (431) 431
piperazines - therapeutic use (423) 423
therapy (415) 415
care and treatment (413) 413
tyrosine kinase inhibitors (409) 409
protein-tyrosine kinases - antagonists & inhibitors (408) 408
mice (385) 385
mutation (384) 384
tyrosine kinase inhibitor (381) 381
antineoplastic agents - pharmacology (369) 369
pyrimidines - adverse effects (353) 353
drug therapy (339) 339
pyrimidines - administration & dosage (323) 323
drug resistance, neoplasm (318) 318
article (316) 316
leukemia, myelogenous, chronic, bcr-abl positive - genetics (312) 312
pharmacology & pharmacy (310) 310
resistance (309) 309
fusion proteins, bcr-abl - genetics (304) 304
protein kinase inhibitors - adverse effects (303) 303
cml (292) 292
analysis (288) 288
follow-up (281) 281
kinases (272) 272
tyrosine kinase (269) 269
chronic-phase (260) 260
protein kinase inhibitors - administration & dosage (257) 257
thiazoles - adverse effects (249) 249
aged, 80 and over (248) 248
activation (245) 245
thiazoles - administration & dosage (244) 244
antineoplastic agents - adverse effects (242) 242
chemotherapy (236) 236
dosage and administration (236) 236
health aspects (234) 234
phosphorylation (231) 231
apoptosis (227) 227
leukemia, myelogenous, chronic, bcr-abl positive - pathology (226) 226
medicine & public health (226) 226
hematology, oncology and palliative medicine (225) 225
src-family kinases - antagonists & inhibitors (224) 224
antineoplastic agents (220) 220
young adult (215) 215
fusion proteins, bcr-abl - antagonists & inhibitors (214) 214
src-family kinases - metabolism (214) 214
dasatinib - therapeutic use (211) 211
cell proliferation - drug effects (209) 209
in-vitro (209) 209
src (209) 209
genetic aspects (207) 207
apoptosis - drug effects (206) 206
expression (206) 206
cytogenetic responses (202) 202
piperazines - pharmacology (202) 202
cell biology (194) 194
abridged index medicus (192) 192
antimitotic agents (192) 192
philadelphia chromosome (192) 192
cells (191) 191
dasatinib - pharmacology (188) 188
antineoplastic agents - administration & dosage (187) 187
imatinib-resistant (187) 187
kinase inhibitor (184) 184
protein-tyrosine kinase (181) 181
signal transduction - drug effects (179) 179
antineoplastic combined chemotherapy protocols - therapeutic use (177) 177
adolescent (176) 176
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3635) 3635
Japanese (54) 54
Chinese (28) 28
French (28) 28
Polish (25) 25
Russian (22) 22
Spanish (17) 17
German (14) 14
Czech (9) 9
Korean (9) 9
Portuguese (6) 6
Turkish (6) 6
Danish (2) 2
Hebrew (2) 2
Slovenian (2) 2
Finnish (1) 1
Hungarian (1) 1
Italian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biosensors and Bioelectronics, ISSN 0956-5663, 12/2016, Volume 86, pp. 879 - 884
Journal Article
Journal Article
Science, ISSN 0036-8075, 07/2019, Volume 365, Issue 6448, p. 41
Journal Article
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 05/2019, Volume 17, Issue 5, pp. 611 - 613
The NCCN Guidelines for Chronic Myeloid Leukemia (CML) criteria for discontinuation of tyrosine kinase inhibitor (TKI) therapy have not seen significant... 
ONCOLOGY | IMATINIB | DASATINIB
Journal Article
Cancer, ISSN 0008-543X, 03/2016, Volume 122, Issue 6, pp. 868 - 874
Journal Article
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 07/2017, Volume 258, pp. 43 - 55
Two novel prodrug polymers POEG- -PSSDas (redox-sensitive) and POEG- -PCCDas (redox-insensitive), which consist of poly(oligo(ethylene glycol) methacrylate)... 
Prodrug micelles | Dasatinib | Redox responsive | Co-delivery | Doxorubicin | DESIGN | DRUG-DELIVERY | OVARIAN-CANCER | ANTITUMOR-ACTIVITY | CHEMISTRY, MULTIDISCIPLINARY | CHRONIC MYELOID-LEUKEMIA | PACLITAXEL | BREAST-CANCER CELLS | FAMILY KINASE INHIBITOR | IMATINIB | PHARMACOLOGY & PHARMACY | MULTIDRUG-RESISTANCE | Prodrugs - administration & dosage | Doxorubicin - therapeutic use | Humans | Dasatinib - pharmacokinetics | Delayed-Action Preparations - chemistry | Polyethylene Glycols - chemistry | Drug Delivery Systems | Micelles | Female | Antibiotics, Antineoplastic - pharmacokinetics | Doxorubicin - administration & dosage | Protein Kinase Inhibitors - pharmacokinetics | Cell Survival - drug effects | Oxidation-Reduction | Dasatinib - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Antibiotics, Antineoplastic - administration & dosage | Protein Kinase Inhibitors - administration & dosage | Animals | Dasatinib - administration & dosage | Antibiotics, Antineoplastic - therapeutic use | Prodrugs - pharmacokinetics | Protein Kinase Inhibitors - therapeutic use | Cell Line, Tumor | Mice, Inbred BALB C | Prodrugs - therapeutic use | Neoplasms - pathology | Ethylene glycol | Anthracyclines | Chemotherapy | Polymers | Analysis | Cancer | Tyrosine | Medical colleges | Pharmacogenetics | Pharmacy | Physiological aspects | Drugstores | co-delivery | dasatinib | doxorubicin | prodrug micelles | redox responsive
Journal Article
European Journal of Clinical Pharmacology, ISSN 0031-6970, 2/2016, Volume 72, Issue 2, pp. 185 - 193
Dasatinib is a novel, oral, multi-targeted kinase inhibitor of breakpoint cluster region-abelson (BCR-ABL) and Src family kinases. The study investigated... 
Dasatinib | Pharmacodynamics | Biomedicine | Half maximal inhibitory concentration | Phamacokinetics | Pharmacology/Toxicology | Molecular response | CELLS | SAFETY | TYROSINE KINASE | NILOTINIB | PHILADELPHIA-CHROMOSOME | IMATINIB | DRUGS | BCR-ABL ACTIVITY | PHARMACOLOGY & PHARMACY | INHIBITOR | Leukocytes, Mononuclear - metabolism | Antigens, CD34 - metabolism | Oncogene Protein v-crk - antagonists & inhibitors | Humans | Middle Aged | Oncogene Protein v-crk - metabolism | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Dasatinib - pharmacokinetics | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Phosphorylation - drug effects | Protein Kinase Inhibitors - pharmacokinetics | Leukocytes, Mononuclear - drug effects | Dasatinib - therapeutic use | Treatment Outcome | Dasatinib - pharmacology | Fusion Proteins, bcr-abl - genetics | Protein Kinase Inhibitors - therapeutic use | Fusion Proteins, bcr-abl - antagonists & inhibitors | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism | Aged | Dasatinib - adverse effects | Protein Kinase Inhibitors - pharmacology | Phosphotransferases | Analysis | Chronic myeloid leukemia | Pharmacology | Kinetics | Drug therapy | Leukemia | Chronic illnesses
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 09/2016, Volume 126, Issue 9, pp. 3207 - 3218
Journal Article
Leukemia & Lymphoma, ISSN 1042-8194, 05/2019, Volume 60, Issue 6, pp. 1568 - 1571
Journal Article
JOURNAL OF CLINICAL ONCOLOGY, ISSN 0732-183X, 02/2017, Volume 35, Issue 5
Journal Article
Cancer, ISSN 0008-543X, 12/2015, Volume 121, Issue 23, pp. 4158 - 4164
Durable remissions and long‐term survival can be achieved with a combination of chemotherapy and dasatinib in patients with Philadelphia chromosome‐positive... 
dasatinib | acute lymphoblastic leukemia | chemotherapy | combination | Philadelphia chromosome | ADULT PATIENTS | ACUTE LYMPHOCYTIC-LEUKEMIA | REGIMEN | HYPER-CVAD | PONATINIB | THERAPY | ONCOLOGY | IMATINIB | MRD | Doxorubicin - therapeutic use | Cyclophosphamide - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Cytarabine - therapeutic use | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Methotrexate - therapeutic use | Cyclophosphamide - therapeutic use | Neoplasm, Residual | Young Adult | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Aged, 80 and over | Vincristine - administration & dosage | Adult | Female | Philadelphia Chromosome | Doxorubicin - administration & dosage | Dexamethasone - administration & dosage | Dasatinib - therapeutic use | Treatment Outcome | Cytarabine - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Dexamethasone - therapeutic use | Dasatinib - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Vincristine - therapeutic use | Methotrexate - administration & dosage | Aged | Dasatinib | Chemotherapy | Usage | Care and treatment | Lymphocytic leukemia | Stem cells | Dosage and administration | Transplantation | Diagnosis | Cancer
Journal Article